Eye Allergy Treatment Market at a CAGR of 5.35% during the forecast period 2024 to 2032

Market Research Future (MRFR) has published on the “Global Eye Allergy Treatment Market”. The Global Eye Allergy Treatment Market is estimated to register a CAGR of 5.35% during the forecast period of 2024 to 2032.

Eye Allergy Treatment Market Highlights

The Global Eye Allergy Treatment Market is expected to register a CAGR of 5.35% during the forecast period and is estimated to reach USD 5.26 billion by 2032. The Global Eye Allergy Treatment Market is emerging due to the increasing prevalence of eye allergies across the world. With an increasing global prevalence of eye allergies, there is a greater demand for effective and innovative treatment options. Additionally, the growing technological advancements and innovation will provide growth opportunities for the market in the future. Also, the market is fueled by new drug launches aimed at meeting high demand.

Key Players

MRFR recognizes the following companies as the key players in the Global Eye Allergy Treatment Market — Johnson & Johnson Services, Inc., Abbvie Inc., Sun Pharmaceutical Industries ltd., Teva Pharmaceutical Industries ltd., Hal Allergy B.V., Novartis AG, Bausch + Lomb, Santen Pharmaceutical Co., ltd., Alcon, Bayer AG

Segment Analysis

The Global Eye Allergy Treatment Market has been segmented based on Type, Drug Class, Treatment Form, Distribution Channel and Region.

Based on type, the global eye allergy treatment market has been segmented into seasonal and perennial allergic conjunctivitis, vernal keratoconjunctivitis, atopic keratoconjunctivitis, contact allergic conjunctivitis, and giant papillary conjunctivitis. The seasonal and perennial allergic conjunctivitis segment dominated the market in 2023, while the atopic keratoconjunctivitis segment is projected to be the fastest-growing segment during the forecast period, 2024-2032. Seasonal allergic conjunctivitis (SAC) and perennial allergic conjunctivitis (PAC) are among the most common forms of eye allergies worldwide. They are triggered by allergens such as pollen, dust mites, and animal dander, affecting a large population during specific seasons or year-round. There are well-established treatment options for Seasonal allergic conjunctivitis (SAC) and perennial allergic conjunctivitis (PAC), including antihistamine eye drops, mast cell stabilizers, corticosteroids, and combination therapies. These treatments effectively alleviate symptoms and manage allergic reactions, contributing to the segment's market dominance.

Based on drug class, the global eye allergy treatment market is segmented into antihistamine, mast cell stabilizer, NSAIDS, corticosteroid, decongestants, immunotherapy allergy shots, and others. The antihistamine segment dominated the market in 2023, while the immunotherapy allergy shots segment is projected to be the fastest-growing segment during the forecast period, 2024-2032. Antihistamines are widely recognized for their ability to block histamine receptors, which are responsible for allergic reactions such as itching, redness, and swelling of the eyes. They provide rapid relief from allergy symptoms. Patients often prefer antihistamines due to their established efficacy, rapid onset of action, and minimal systemic side effects compared to other drug classes. Antihistamines have been fundamental in allergy treatment for many years, with extensive clinical research supporting their efficacy and safety. This strong foundation of evidence built a confidence in healthcare providers and patients alike, contributing their ongoing dominance in eye allergy treatment market.

Based on treatment form, the global eye allergy treatment market is segmented into eyedrops, injectables, and tablets & capsules. The eyedrops segment dominated the market in 2023, while the injectables segment is projected to be the fastest-growing segment during the forecast period, 2024-2032.

Eyedrops are specifically formulated for direct application to the eyes, allowing for targeted delivery of medications to relieve symptoms such as itching, redness, and irritation associated with eye allergies. This direct application provides rapid relief and is convenient for patients. They are generally easy to administer and can be used multiple times a day as needed. Patients appreciate the simplicity and non-invasive nature of eyedrop treatments compared to injectables or oral medications. Many eyedrop formulations for mild to moderate eye allergies are available over the counter (OTC), making them easily accessible without requiring a prescription. This accessibility contributes to their widespread use and market dominance.

Based on distribution channel, the global eye allergy treatment market is segmented into hospital pharmacies, online pharmacy, and retail pharmacy. The hospital pharmacies segment dominated the market in 2023, while the retail pharmacy segment is projected to be the fastest-growing segment during the forecast period, 2024-2032.Hospital pharmacies ensure immediate access to a wide range of medications required for treating severe or acute eye allergies. This includes injectables, specialized eye drops, and medications that may not be readily available in retail pharmacies or online. For patients experiencing severe allergic reactions affecting the eyes, hospital pharmacies offer emergency care and critical support. Therefore, Hospital pharmacies play a pivotal role in the eye allergy treatment market due to their capacity to deliver specialized care, prompt access to medications, emergency readiness, strict adherence to regulatory standards, and seamless integration into healthcare systems. These elements combine to establish their dominance in effectively managing and treating diverse types of eye allergies.

Browse In-depth Market Details [Table of Content, List of Figures, List of Tables] of Eye Allergy Treatment Market Research Report

Regional Analysis

Based on region, the global eye allergy treatment market has been segmented into North America, Europe, Asia-Pacific, and the Rest of the World. North America accounted for the largest market share in 2023 and is anticipated to reach USD 1.94 billion by 2032, registering a CAGR of 4.29% during the forecast period. However, Asia-Pacific is projected to grow at the highest CAGR of 7.11% during the forecast period.

The growth of the Americas is due to its rising geriatric population and increasing ophthalmological disorders, causing an increased need for diagnosis and therapeutics. in February 2020, Alcon, a Novartis AG (US) company, reported that there were nearly 66 million Americans suffering from eye allergies. This huge prevalence of eye allergies is driving the growth of the eye allergy treatment market.

Americas region is followed by Europe, which accounted for the second largest eye allergy treatment market share owing to the rising patient population with eye disorders, availability of advanced treatment facilities, increasing healthcare expenditure, and the introduction of advanced therapies into the market along with the presence of good healthcare infrastructure. Additionally, rising government initiatives are driving the growth of the market. Moreover, the increasing geriatric population is also fueling the growth of the eye allergy treatment market. For instance, as per Senior Home Plus (UK), eye allergies in the elderly population occur due to a weakened immune system, chronic health conditions, reduced tear production, and some medication side effects that have been prescribed to the elderly population. market for significant growth.

Asia-Pacific is the fastest-growing market for the global eye allergy treatment market. The presence of a huge patient population, rapid development in technology, and the presence of huge opportunities for the development of the market drive the growth of the eye allergy treatment market in Asia-Pacific. Additionally, the rising elderly population is also fueling the market of eye allergy treatments in this region.  As per the Asia-Pacific Report on Population Ageing 2022, there were approximately 670 million people aged 60 or older in Asia-Pacific in 2022. Thus, the increasing prevalence of eye allergies and the growing geriatric population are burgeoning the growth of the global market.

Key Findings of the Study

• The Global Eye Allergy Treatment Market is expected to reach USD 5.26 billion by 2032, at a CAGR of 5.35% during the forecast period.


• The North America region market is estimated to hold the largest market share in the Global Eye Allergy Treatment market.


• Based on type, the seasonal and perennial allergic conjunctivitis segment dominated the market in 2023


• Johnson & Johnson Services, Inc., Abbvie Inc., Sun Pharmaceutical Industries ltd., Teva Pharmaceutical Industries ltd., Hal Allergy B.V., Novartis AG, Bausch + Lomb, Santen Pharmaceutical Co., ltd., Alcon, Bayer AG are the key market players.